本帖最后由 老马 于 2013-3-13 13:43 编辑
2 g- ]0 ]( T1 O9 s
4 X+ j0 E0 r* N# g% q& r( Y健择（吉西他滨）+顺铂+阿瓦斯汀
8 y1 p) C, y& l+ Z% ~" U; E Gemzar +Cisplatin + Avastin
, g* s3 [+ W, P2 S( Q9 J# v+ Nhttp://annonc.oxfordjournals.org/content/21/9/1804.full: g8 a" d! j- ?5 I9 `4 [& s/ s' n
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ q& z& Y) B p5 H0 E$ X2 GPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
9 J) ]6 Y+ x; }2 Z* tResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. ; v0 N/ I B) i# w: B% w' Q, S9 @
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
& `7 f7 i5 P0 t. l4 S2 @华为网盘附件：- c y/ C: V N+ q/ F9 L+ W
【华为网盘】ava.JPG+ I& U i4 h+ [7 i& }3 w
|
11011102001537 )
显身卡
